SCHEMBL8224441

SCHEMBL8224441

O=C(O)c1c(Cl)ccc(F)c1Br

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.50
ALDH1A1 P00352 3/20 0.44
KDM4E B2RXH2 1/20 0.44
HSD17B10 Q99714 1/20 0.44
TP53 P04637 1/20 0.39
TSHR P16473 3/20 0.36
SLC2A1 P11166 1/20 0.36
RPA1 P27694 1/20 0.36
GAA P10253 4/20 0.36
ADRA2A P08913 1/20 0.36
CLCN2 P51788 1/20 0.36
ALOX15 P16050 1/20 0.35
CASP1 P29466 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
FABP3 P05413 1/20 0.35
FABP4 P15090 1/20 0.35
ANO1 Q5XXA6 1/20 0.35
PBRM1 Q86U86 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17007116 0.83 CES2 (0.41) DPP4KDM4E
SCHEMBL28299440 0.83 DPP4 (0.58) DPP4ALDH1A1KDM4EHSD17B10TP53
SCHEMBL24456032 0.79 DPP4 (0.54) DPP4ALDH1A1KDM4EHSD17B10TP53
SCHEMBL1358784 0.79 DPP4 (0.54) DPP4ALDH1A1KDM4EHSD17B10TP53
SCHEMBL25679318 0.78 CA1 (0.46) DPP4ALDH1A1KDM4EHSD17B10GAA
SCHEMBL29181700 0.78 DPP4 (0.52) DPP4ALDH1A1KDM4EHSD17B10TP53
Potassium SCHEMBL30811378 0.78 DPP4 (0.52) DPP4ALDH1A1KDM4EHSD17B10TP53
SCHEMBL24717969 0.78 CYP1A2 (0.41) ALDH1A1KDM4ETSHRALOX15CASP1
SCHEMBL1467095 0.77 DPP4 (0.50) DPP4ALDH1A1KDM4EHSD17B10TP53
SCHEMBL31193466 0.76 DPP4 (0.60) DPP4ALDH1A1KDM4EHSD17B10TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119775121-A Synthetic method of multi-halogen substituted fluorine-containing 2-bromobenzoic acid compound 上海毕得医药科技股份有限公司 2025-04-08 CN disclosed
US-RE49556-E1 Compounds and compositions as protein kinase inhibitors ARRAY BIOPHARMA INC. (US) 2023-06-20 US disclosed
US-20230116233-A1 Compounds And Compositions As Protein Kinase Inhibitors ARRAY BIOPHARMA INC (US) 2023-04-13 US disclosed
US-20200323852-A1 Compounds And Compositions As Protein Kinase Inhibitors IRM LLC (BM) 2020-10-15 US disclosed
US-10576080-B2 Compounds and compositions as protein kinase inhibitors ARRAY BIOPHARMA INC. (US) 2020-03-03 US disclosed
US-10568884-B2 Compounds and compositions as protein kinase inhibitors ARRAY BIOPHARMA INC. (US) 2020-02-25 US disclosed
US-20180297986-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2018-10-18 US disclosed
US-20180297985-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2018-10-18 US disclosed
US-10005761-B2 Compounds and compositions as protein kinase inhibitors ARRAY BIOPHARMA INC. (US) 2018-06-26 US disclosed
US-9850229-B2 Compounds and compositions as protein kinase inhibitors ARRAY BIOPHARMA, INC. (US) 2017-12-26 US disclosed
US-20160120866-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS NOVARTIS AG (CH) 2016-05-05 US disclosed
US-9314464-B2 Compounds and compositions as protein kinase inhibitors NOVARTIS AG (CH) 2016-04-19 US disclosed
EP-2470526-B1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2014-05-28 EP disclosed
EP-2727918-A1 Compounds and Compositions as Protein Kinase Inhibitors IRM LLC (BM) 2014-05-07 EP disclosed
US-20130296318-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS ARRAY BIOPHARMA, INC. 2013-11-07 US disclosed
US-8501758-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2013-08-06 US disclosed
CN-102725283-A Compounds and compositions as protein kinase inhibitors IRM LLC 2012-10-10 CN disclosed
EP-2470526-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2012-07-04 EP disclosed
US-20110306625-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS NOVARTIS AG (CH) 2011-12-15 US disclosed
WO-2011025927-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2011-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200323852-A1 Compounds And Compositions As Protein Kinase Inhibitors BRAF, RAF1, ARAF DPP4 3889/4885ALDH1A1 4023/4885KDM4E 2572/4885
US-20110306625-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS BRAF, RAF1, ARAF DPP4 3889/4885ALDH1A1 4023/4885KDM4E 2572/4885
US-20130296318-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS BRAF, RAF1, ARAF DPP4 3889/4885ALDH1A1 4023/4885KDM4E 2572/4885
US-10005761-B2 Compounds and compositions as protein kinase inhibitors BRAF, RAF1, ARAF DPP4 3889/4885ALDH1A1 4023/4885KDM4E 2572/4885
US-10568884-B2 Compounds and compositions as protein kinase inhibitors BRAF, RAF1, ARAF DPP4 3889/4885ALDH1A1 4023/4885KDM4E 2572/4885
US-20180297985-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS BRAF, RAF1, ARAF DPP4 3889/4885ALDH1A1 4023/4885KDM4E 2572/4885
US-20230116233-A1 Compounds And Compositions As Protein Kinase Inhibitors BRAF, RAF1, ARAF DPP4 3889/4885ALDH1A1 4023/4885KDM4E 2572/4885
US-20180297986-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS BRAF, RAF1, ARAF DPP4 3889/4885ALDH1A1 4023/4885KDM4E 2572/4885
US-10576080-B2 Compounds and compositions as protein kinase inhibitors BRAF, RAF1, ARAF DPP4 3889/4885ALDH1A1 4023/4885KDM4E 2572/4885
US-20160120866-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS BRAF, RAF1, ARAF DPP4 3889/4885ALDH1A1 4023/4885KDM4E 2572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.